Synaptogenix president daniel l. alkon, m.d.

Bryostatin-1 benefits in severe alzheimer's disease patients were statistically significant with respect to placebo at p < 0.007 new york , dec. 19, 2023 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx) ("synaptogenix" or the "company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its president and chief scientific officer, daniel l. alkon, m.d.
SNPX Ratings Summary
SNPX Quant Ranking